Biotech Values

[biotech jim]

I guess biotech deal price is going up.

At least for the percieved 'validated' mechanisms. Now I would not say that JAK(s) inhibitors are a validated mechanism for RA yet, but getting real close. Subtype complexity may not be an issue.

I suspect ABT management was asking the licensing and discovery groups where their JAK inhibitor was. On top of Humira, this is a pretty good bet on oral RA drugs IMO.